Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 and Capecitabine in Solid Tumors
NCT05803382Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZEN3694 in solid tumor and colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events, Maximum tolerated dose and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05803382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803382.